(BPT) - For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that one in three will see their cancer return — typically within a year following completion of their initial treatment. [1] Today, the current standard of care following initial chemotherapy is to "watch and wait," an approach that monitors the patient for signs of relapse.

But what if there were a way to identify patients at risk of relapse earlier and treat them before the cancer has a chance to come back? That's the goal of the ALPHA3 clinical trial, a groundbreaking study investigating whether early intervention with an investigational CAR T cell product (cemacabtagene ansegedleucel

See Full Page